Celldex Therapeutics (CLDX) Accounts Payables (2010 - 2026)

Celldex Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $10.4 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 203.78% year-over-year to $10.4 million in Q1 2026; TTM through Mar 2026 was $10.4 million, a 203.78% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, down 63.86% from the prior year.
• Accounts Payables climbed to $10.4 million in Q1 2026 per CLDX's latest filing, from $1.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $10.4 million in Q1 2026 and bottomed at $881000.0 in Q2 2023.
• The 5-year median for Accounts Payables is $3.3 million (2024), against an average of $3.0 million.
• Biggest YoY gain for Accounts Payables was 331.56% in 2024; the steepest drop was 68.93% in 2024.
• Year by year, Accounts Payables stood at $3.3 million in 2022, then advanced by 4.61% to $3.5 million in 2023, then retreated by 6.55% to $3.3 million in 2024, then slumped by 63.86% to $1.2 million in 2025, then surged by 777.88% to $10.4 million in 2026.
• Per Business Quant, the three latest CLDX Accounts Payables figures stand at $10.4 million (Q1 2026), $1.2 million (Q4 2025), and $4.3 million (Q3 2025).